Health Care Innovation
Health Care
Why Pharmaceutical Prices Drop Once Drugs Are Off-Patent
Today PRI released the new report The Economics of Pharmaceutical Pricing by PRI senior fellow Wayne Winegarden, Ph.D. The study examines the market forces influencing the often dramatic price differences in pharmaceutical drugs before and after their patents expire. Some critics erroneously see the sharp declines in the prices of ...
Commentary
Industry Succeeds Where Obamacare Fails
Walmart is about to get into the health insurance business. The retail giants Sams Club division just announced that it would launch a private health insurance exchange for its small-business customers. Business owners shopping at the wholesaler will effectively be able to pick up health insurance for their employees along ...
Commentary
The News Is The Declining Incentives For Medical Innovation
The federal health exchange Healthcare.gov, one of the centerpieces of the Affordable Care Act (ACA or ObamaCare), is gasping for life. This is not the important story, however. The U.S. health care system has flaws. And, these flaws should have been the focus of the health care reforms back in ...
Commentary
India’s War On Intellectual Property Rights May Bring With It A Body Count
Last month, drug maker Roche withdrew its patents for the breast-cancer drug Herceptin in India and thus gave tacit approval to other companies to make low-cost generic versions of the drug. But the withdrawal of those patents was not completely voluntary. If the Swiss pharmaceutical firm had not relinquished ...
Commentary
Government Mandates Don’t Lower Health Care Costs
Free lunches are often the most expensive meals. And yet, when it comes to the nations health care system, the federal government blindly offers free lunch buffets in lieu of policies that would actually address the core problems of the nations health care system. An example of this free lunch ...
Commentary
Bend The Healthcare Cost Curve Downward By Letting Healthcare Costs Rise
Earlier this year, a team of researchers in Europe decided to examine the relationship between cutting-edge technology and healthcare costs. Some wonks complain that expensive new medical technologies and therapies some of which deliver only marginal improvements to patient health are key drivers of health spending. But when ...
Commentary
Treating Alzheimer’s with regulations
Bureaucracy stands in the way of the best treatment The U.S. health care system is rife with rising costs and stagnating quality. All too often, the cure for these ailments calls for ever greater government intervention. Such cures misdiagnose the problem. The health care systems problems are caused by too ...
Commentary
Big Pharma Accomplishes Big Things, Yet Obama Is Suffocating The Industry
Whats the most research-intensive industry in America? If you guessed Silicon Valley or the energy sector, guess again. In fact, its the drug industry. The 31 pharmaceutical companies comprising its main trade group spent $48.5 billion on research and development last year. All told, the pharmaceutical sector has spent $550 ...
Health Care
Myths and Realities of Obamacare
Introduction Three years ago on March 23, 2010, the Patient Protection and Affordability Act (Obamacare) was signed into law. With the U.S. Supreme Court ruling on June 28, 2012 that the individual mandate is constitutional under Congress power to tax and the November 6 election results, the law is in ...
Commentary
The Lifesaving Promise Of The Pharmaceutical Drug Pipeline
There was a time not long ago when patients suffering from rare diseases had little hope of finding a medicine that could cure their ills. But in the 30 years since Congress passed the Orphan Drug Act, research into orphan drugs defined as those treating diseases that affect fewer ...
Why Pharmaceutical Prices Drop Once Drugs Are Off-Patent
Today PRI released the new report The Economics of Pharmaceutical Pricing by PRI senior fellow Wayne Winegarden, Ph.D. The study examines the market forces influencing the often dramatic price differences in pharmaceutical drugs before and after their patents expire. Some critics erroneously see the sharp declines in the prices of ...
Industry Succeeds Where Obamacare Fails
Walmart is about to get into the health insurance business. The retail giants Sams Club division just announced that it would launch a private health insurance exchange for its small-business customers. Business owners shopping at the wholesaler will effectively be able to pick up health insurance for their employees along ...
The News Is The Declining Incentives For Medical Innovation
The federal health exchange Healthcare.gov, one of the centerpieces of the Affordable Care Act (ACA or ObamaCare), is gasping for life. This is not the important story, however. The U.S. health care system has flaws. And, these flaws should have been the focus of the health care reforms back in ...
India’s War On Intellectual Property Rights May Bring With It A Body Count
Last month, drug maker Roche withdrew its patents for the breast-cancer drug Herceptin in India and thus gave tacit approval to other companies to make low-cost generic versions of the drug. But the withdrawal of those patents was not completely voluntary. If the Swiss pharmaceutical firm had not relinquished ...
Government Mandates Don’t Lower Health Care Costs
Free lunches are often the most expensive meals. And yet, when it comes to the nations health care system, the federal government blindly offers free lunch buffets in lieu of policies that would actually address the core problems of the nations health care system. An example of this free lunch ...
Bend The Healthcare Cost Curve Downward By Letting Healthcare Costs Rise
Earlier this year, a team of researchers in Europe decided to examine the relationship between cutting-edge technology and healthcare costs. Some wonks complain that expensive new medical technologies and therapies some of which deliver only marginal improvements to patient health are key drivers of health spending. But when ...
Treating Alzheimer’s with regulations
Bureaucracy stands in the way of the best treatment The U.S. health care system is rife with rising costs and stagnating quality. All too often, the cure for these ailments calls for ever greater government intervention. Such cures misdiagnose the problem. The health care systems problems are caused by too ...
Big Pharma Accomplishes Big Things, Yet Obama Is Suffocating The Industry
Whats the most research-intensive industry in America? If you guessed Silicon Valley or the energy sector, guess again. In fact, its the drug industry. The 31 pharmaceutical companies comprising its main trade group spent $48.5 billion on research and development last year. All told, the pharmaceutical sector has spent $550 ...
Myths and Realities of Obamacare
Introduction Three years ago on March 23, 2010, the Patient Protection and Affordability Act (Obamacare) was signed into law. With the U.S. Supreme Court ruling on June 28, 2012 that the individual mandate is constitutional under Congress power to tax and the November 6 election results, the law is in ...
The Lifesaving Promise Of The Pharmaceutical Drug Pipeline
There was a time not long ago when patients suffering from rare diseases had little hope of finding a medicine that could cure their ills. But in the 30 years since Congress passed the Orphan Drug Act, research into orphan drugs defined as those treating diseases that affect fewer ...
